Listed by the USPTO as DUTT, ADITI
Tech Center 1600 • Art Units: 1642 1649 1675
This examiner grants 47% of resolved cases
DUTT, ADITI is a USPTO patent examiner in tech center 1600 and art unit 1642. The profile records 385 resolved cases, a 46.8% allowance rate, and a median of 1471 days to allowance. Interviews have a 48.5% lift, indicating a strong positive association and making examiner engagement a potentially important part of prosecution planning.
The listed companies are Novartis AG, Hoffmann-La Roche Inc., and Wisconsin Alumni Research Foundation. The listed firms are BALLARD SPAHR LLP, COOLEY LLP, and Fox Rothschild LLP - JHU. Practitioners can combine interview preparation with careful claim and prior-art analysis, while using the pendency figure to set realistic portfolio expectations.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17111820 | PEPTIDIC LINKER WITH REDUCED POST-TRANSLATIONAL MODIFICATION | Final Rejection | Hoffmann-La Roche Inc. |
| 19575321 | THERAPEUTIC ANTI-BAFF-R ANTIBODIES | Non-Final OA | Novartis AG |
| 18363237 | MOLECULES THAT BIND TO AND STABILIZE TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 (TREM2) | Non-Final OA | Novartis AG |
| 17973020 | Simplified Compositions and Methods for Generating Neural Stem Cells from Human Pluripotent Stem Cells | Non-Final OA | Wisconsin Alumni Research Foundation |
| 16379763 | IMMORTALIZATION OF CELLS INCLUDING NEURONAL CELLS | Non-Final OA | The Johns Hopkins University |
| 17925235 | BIOMARKER FOR DIAGNOSIS OF DEMENTIA | Non-Final OA | TOHOKU UNIVERSITY |
| 17809376 | EXPRESSION OF NEUROPEPTIDES | Non-Final OA | California Institute of Technology |
| 18289317 | DOSING REGIMEN FOR COMBINATION THERAPY TARGETING DLL3 AND PD-1 | Non-Final OA | AMGEN INC. |
| 17864285 | ENZYME DELIVERY SYSTEMS AND METHODS OF PREPARATION AND USE | Final Rejection | Curemark, LLC |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy46.8% of resolved applications examined by Aditi Dutt were allowed (385 resolved cases), compared with 38.5% across Art Unit 1642 over the last five years.
This examiner's interview lift is +48.5 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Aditi Dutt took 1,471 days on average from filing to allowance.
Aditi Dutt examines applications in Art Unit 1642 in Tech Center 1600 (Biotechnology & Pharmaceuticals).
